Redeye returns with an updated view following Elicera’s Q2 report and encouraging data from the phase I/II CARMA study, evaluating ELC-301 in diffuse large B-cell lymphoma (DLBCL). In light of the new data, we raise our likelihood of approval (LoA) assumptions for ELC-301 and make minor positive commercial adjustments, resulting in a higher valuation range.
LÄS MER
